LPCN Lipocine Inc.

1.82
0  0%
Previous Close 1.82
Open
Price To Book 3.57
Market Cap 39,266,414
Shares 21,574,953
Volume 0
Short Ratio
Av. Daily Volume 136,381

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released September 2016. Seeking feedback from FDA regarding Phase 3 design.
LPCN 1111
Oral testosterone product
CRL issued June 2016. Further CRL issued May 9, 2018. PDUFA date November 9, 2019.
TLANDO - LPCN 1021
Men with low testosterone (Low T)
Conduct food/fact effect study in preparation for Phase 3 trial.
LPCN 1107
Prevention of preterm birth ("PTB").
Phase 2 dosing to commence 3Q 2019.
LPCN 1144
Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Is Lipocine Inc.'s (NASDAQ:LPCN) Balance Sheet Strong Enough To Weather A Storm?
  2. LPCN: Now We Have PDUFA Date; Target To $7
  3. Lipocine Announces TLANDO™ NDA PDUFA Action Date of November 9, 2019
  4. Lipocine: 1Q Earnings Snapshot
  5. Lipocine Announces First Quarter 2019 Financial and Operational Results
  6. Did You Manage To Avoid Lipocine's (NASDAQ:LPCN) Devastating 81% Share Price Drop?
  7. LPCN: Turning the Tables
  8. Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy
  9. LPCN: ABPM Study Topline Data
  10. Lipocine Announces ABPM Labeling Study Results Consistent with Recently Approved Testosterone Replacement Therapy
  11. Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers
  12. Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference
  13. LPCN: NASH Topline
  14. Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019
  15. Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate
  16. Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population
  17. Lipocine Announces Financial and Operational Results for the Year Ended December 31, 2018
  18. Does Lipocine Inc.’s (NASDAQ:LPCN) CEO Pay Reflect Performance?
  19. Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects
  20. LPCN: Soldiering on and Winning Some Battles